title: Possible effects of hepatocyte growth factor for the prevention of peritoneal fibrosis.
abstract: OBJECTIVE
  Some patients who had carried out long-term continuous ambulatory peritoneal dialysis discontinued the treatment because of progressive peritoneal fibrosis. It has been previously reported that transforming growth factor-beta1 (TGF-beta1) is one of the factors that induces peritoneal fibrosis. Also, hepatocyte growth factor (HGF) plays a role in the prevention of fibrosis and in inhibiting TGF-beta1 production. In this study, we examined the effects of HGF on peritoneal fibrosis by TGF-beta1 induced by high concentrations of D-glucose.
  
  
  METHODS
  We transfected a full-length human HGF cDNA in an expression vector into human peritoneal mesothelial cells (HPMCs) using the calcium phosphate method. Transfected HPMCs were cultured with high concentrations of D-glucose solution and co-cultured with fibroblasts using a transwell system. Cell proliferation was determined using the Tetra Color One method. TGF-beta1 and HGF protein were measured by enzyme-linked immunosorbent assay.
  
  
  RESULTS
  In addition to recombinant HGF, the growth inhibition of HPMCs by high concentration D-glucose or TGF-beta1 was significant. By transfecting HGF cDNA into HPMCs, growth inhibition by high concentration D-glucose was completely restored. Furthermore, the production of TGF-beta1 was also significantly decreased.
  
  
  CONCLUSIONS
  These results suggested that exogenous HGF could possibly prevent peritoneal fibrosis.
authors.affiliation: Department of Hematology, Kinki University School of Medicine, Osaka, Japan.
authors.forename: Koki
authors.initials: K
authors.lastname: Matsuo
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Maeda
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Naiki
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Matsuoka
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Tamai
authors.forename: Satoru
authors.initials: S
authors.lastname: Yonekawa
authors.forename: Mika
authors.initials: M
authors.lastname: Sakaguchi
authors.forename: Ichiro
authors.initials: I
authors.lastname: Iwamoto
authors.forename: Hirohumi
authors.initials: H
authors.lastname: Hasegawa
authors.forename: Kunio
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Nakamura
authors.forename: Akihisa
authors.initials: A
authors.lastname: Kanamaru
mesh_terms: D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D018920:Coculture Techniques; D004847:Epithelial Cells / Q000187:drug effects; D005355:Fibrosis / Q000517:prevention & control*; D005947:Glucose / Q000494:pharmacology; D017228:Hepatocyte Growth Factor / Q000627:therapeutic use*; D006801:Humans; D009852:Omentum / Q000166:cytology; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D010537:Peritoneum / Q000473:pathology*; D011994:Recombinant Proteins / Q000627:therapeutic use; D014162:Transfection; D016212:Transforming Growth Factor beta / Q000009:adverse effects / Q000378:metabolism; D053773:Transforming Growth Factor beta1
chemical_list: C066855:HGF protein, human; D011994:Recombinant Proteins; C508960:TGFB1 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D017228:Hepatocyte Growth Factor; D005947:Glucose